Takimoto Chris H 4

What Happened

• Chris H. Takimoto, a director of ALX Oncology Holdings, was granted a derivative award covering 40,400 shares on January 20, 2026. The Form 4 reports the transaction as an award/acquisition (code A) with a reported price of $0.00 and total reported value of $0 (derivative instrument).
• This is a compensation-style grant (not an open-market purchase or sale). The filing does not show an immediate cash transaction or sale of shares.

Key Details

• Transaction date: 2026-01-20; Form 4 filed 2026-01-21 (appears timely).
• Reported security: derivative award covering 40,400 shares (option/award); reported price $0.00; total reported value $0.
• Shares owned after the transaction: not specified in the summary of this filing.
• Footnote: Shares subject to the option vest in 12 equal monthly installments beginning February 20, 2026.
• Transaction code: A = Award/Grant (derivative).

Context

• This appears to be a time-based options/award grant as part of compensation; vesting over 12 months means the recipient must remain in service to realize the full award.
• Such grants are common for directors and executives and reflect compensation arrangements rather than an immediate bullish or bearish trading signal.